Leerink Partnrs Reduces Earnings Estimates for uniQure

uniQure (NASDAQ:QURE) – Equities research analysts at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for shares of uniQure in a report released on Tuesday, December 10th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings of ($2.39) per share for the year, down from their prior forecast of ($2.28). The consensus estimate for uniQure’s current full-year earnings is ($3.81) per share. Leerink Partnrs also issued estimates for uniQure’s Q4 2024 earnings at $1.14 EPS, Q1 2025 earnings at ($1.07) EPS, Q2 2025 earnings at ($1.27) EPS, Q3 2025 earnings at ($1.53) EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at ($3.66) EPS and FY2026 earnings at ($1.08) EPS.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million.

A number of other brokerages also recently issued reports on QURE. StockNews.com upgraded uniQure to a “sell” rating in a research report on Wednesday. The Goldman Sachs Group raised their price target on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday. Cantor Fitzgerald lifted their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $20.00 to $52.00 in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.14.

uniQure Price Performance

NASDAQ QURE opened at $15.40 on Friday. The firm’s 50-day simple moving average is $7.04 and its two-hundred day simple moving average is $6.36. The company has a market cap of $750.60 million, a PE ratio of -3.10 and a beta of 0.89. uniQure has a 52 week low of $3.73 and a 52 week high of $17.39. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

Insider Transactions at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QURE. RTW Investments LP bought a new position in uniQure in the 3rd quarter worth $49,000. China Universal Asset Management Co. Ltd. grew its holdings in uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares in the last quarter. Atria Investments Inc bought a new position in shares of uniQure during the third quarter worth $53,000. Quarry LP purchased a new position in uniQure during the third quarter valued at $58,000. Finally, Vanguard Personalized Indexing Management LLC increased its holdings in uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,306 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.